Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome

Lupus

Volumn 7, Issue 4, 1998, Pages 238-258

  Lhote, F ^a   Cohen, P ^b   Guillevin, L ^b  

^a DELAFONTAINE HOSPITAL   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Churg Strauss syndrome; Corticosteroids; Cyclophophamide; Microscopic polyangiitis; Polyarteritis nodosa

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ALLERGIC RHINITIS; ASTHENIA; ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FEVER; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEPATITIS B; HUMAN; HYPEREOSINOPHILIA; HYPERTENSION; KIDNEY DISEASE; MUSCULOSKELETAL DISEASE; NECROTIZING ARTERITIS; PERIPHERAL NEUROPATHY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; SKIN DISEASE; SYSTEMIC VASCULITIS; WEIGHT REDUCTION;

CHURG-STRAUSS SYNDROME; HUMANS; POLYARTERITIS NODOSA; SURVIVAL RATE; VASCULITIS;

EID: 0031777901     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920055     Document Type: Review

References (119)

1. Küssmaul A, Maier R, Ueber eine bischer nicht beschriebene eigenthümliche Arterienerkrankung (Penarteritis nodosa) die mit Morbus Brightu und rapid forstschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1986; 1: 483.
2. Adu D et al. Polyarteritis and the kidney. Q J Med 1987; 62: 221-237.
3. D'Agati et al. Idiopathic microscopic polyarteritis nodosa: ultrastructural observations on the renal vascular and glomerular lesions. Am J Kidney Dis 1986; 7: 95-110.
4. Gordon M et al. Relapses in patients with a systemic vasculitis. Q J Mrd 1993; 86; 779-789.
5. Savage COS et al. Microscopic polyartentis: presentation, pathology and prognosis. Q J Med 1985; 56: 467-483.
6. Serra A et al. Vasculitis affecting the kidney: presentation, histopathology and long-term outcome. Q J Med 1984; 53: 181-207.
7. Guillevin L et al. Microscopic polyangiitis: clinical symptoms, laboratory findings and outcome in 89 patients. Arthritis Rheum 1997; 40 (Supplement): S169 (abstract 828).
8. Jennette JC et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
9. Jennette JC, Falk RJ. Small-vessel vasculitis. New Engl J Med 1997; 337: 1512-1523.
10. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol 1951; 27: 277-301.
11. Lanham et al. Systemic vasculitis with asthma and cosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63: 65-81.
12. Cohen P et al. and the French Polyarteritis Nodosa Study Group Clinical aspects and long survival of 85 patients with Churg - Strauss syndrome Arthritis Rheum 1995; 38 (Supplement 9): S. 391 [abstract 1438].
13. Gocke DJ et al. Association between polyarteritis nodosa and Australia antigen. Lancet 1970; 2:1149-1150.
14. Guillevin L et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74: 238-253.
15. Zeek PM. Periarteritis nodosa: a critical review. Am J Clin Pathol 1952; 22: 777-790.
16. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations Ann Intern Med 1978; 89: 660-676.
17. Lightfoot RW et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33: 1088-1093.
18. Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21: 883-910.
19. Cohen Tervaert JW, Kallemberg C. Neurologic manifestations of systemic vasculitides. Rheum Dis Clin North Am 1993; 19: 913-940.
20. Lie JT. Nomenclature and classification of vasculitis: plus ça change, plus c'est la même chose. Arthritis Rheum 1994; 37: 181-186.
21. Guillevin L, Lhote F. Distinguishing polyarteritis nodosa from microscopic polyangiitis. Curr Opin Rheumatol 1995; 7: 20-24.
22. Hagen EC et al. Anti-neutrophil cytoplasm autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood 1993; 81: 1996-2002.
23. Van der Woud FJ et al. Autoantibodies against neutrophils and monocytes; tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; i: 425-429.
24. Kallenberg GCM, Mulder AHL, Cohen Tervaert JW. Antineutrophil cytoplasmic autoantibodies: a still-growing class of autoantibodies in inflammatory disorders. Am J Med 1992; 93: 675-682.
25. Savage COS. Interactions between leukocytes, the vascular endothelium and autoantibodies in the development of systemic vasculitis. Ann Méd Interne (Paris) 1993; 144: 353-356.
26. Gross WL, Csernok E. Immunodiagnostic pathophysiologic aspects of antmeutrophil cytoplasmic antibodies in vasculitis, Curr Opin Rheumatol 1995; 7: 11-19.
27. Brasile L et at. Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis Am J Med 1989; 87: 74-80.
28. Dtreskeneli H et al Autoantibodies against endothelial cells, extracellular matrix, and human collagen type IV in patients with systemic vasculitis. Chin Immunol Immunopathol 1994; 70: 206-210.
29. Savage COS et ai. Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 1991; 85: 14-19.
30. Kallenberg CGM. Autoantibodies in vasculitis: current perspectives. Clin Exp Rheumatol 1993; 11: 355-360.
31. Del Papa N et al. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clin Immunol Immunapathol 1992; 63: 267-274.
32. Del Papa N et al. Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce molecule expression and cytokine secretion Arthritis Rheum 1996; 39: 758-766.
33. Grau GE et al. Serum cytokine changes in systemic vasculitis. Immunology 1989; 68: 196-198.
34. Kelow J et al. Pro- and anti-inflammatory cytokines in primary systemic vasculitis. In: Gross WL (ed). ANCA-associated vasculitis. Plenum Press. New York and London, 1993 pp 341-344.
35. Cid MC et al. Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. Arthritis Rheum 1994; 37: 1055-1061.
36. Conn DL. In: Khippel JH, Dieppe P (eds). Rheumatology Mosby-Year Book Europe Ltd: London, 1994, pp 6-17 1-6-17.10.
37. Gherardi R et al. The spectrum of vasculitis in human immunodeficiency virus-infected patients. A clinicopathologic evaluation. Arthritis Rheum 1993; 36: 1164-1174
38. Gaches F et al. Périartérite noueuse et infection par le parvovirus B 19. Rev Méd Interne 1993; 14: 323-325
39. Finkel TH et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aeteological agent? Lancet 1994; 343: 1255-1258.
40. Vernant JC et al. Vascularites et manifestations neurologiques liées au HTLV-1. Presse Méd 1994; 23: 1421-1427.
41. Carson CW et al. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 1993; 20: 304-309.
42. Frohnert PP, Sheps SG. Long-term follow-up study of periartentis nodosa. Am J Med 1967; 43: 8-14.
43. Sach M, Cassidy JT, Bole GG. Prognostic factors in polyarteritis J Rheumatol 1975; 2: 411-420.
44. Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67: 941-947.
45. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis and rcsponse to treatment in polyarteritis. Mayo Clin Proc 1980; 55:148-155.
46. Guillevin L et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol 1988; 27: 258-264
47. Guillevin L et al Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Méd Interne (Paris) 1992; 143: 405-416.
48. Fortin PR et al. Prognosis factors in systemic necrotizing vasculitis of the polyarteritis nodosa group. A review of 45 cases. J Rheumatol 1995; 22: 78-84.
49. Azar N et al. Symptomatic urogenital manifestations of polyarteritis nodosa and Churg-Strauss angiitis J Urol 1989; 142: 136-138.
50. Smith DL, Wernick R. Spontaneous rupture of a renal artery aneurysm in polyarteritis nodosa: critical review of the literature and report of a case. Am J Med 1989; 87: 464-467.
51. Guillevin L et al. Gastro-intestinal tract involvement in polyarteritis nodosa and Churg-Strauss syndrome. Ann Méd Inlerne (Parts) 1995; 146: 260-267.
52. Le Thi Huong et al. Les manifestations digestives de la périartéritc noueuse dans une série de 120 case. Gastroentérol Clin Biol 1985; 9: 697-703.
53. Généreau T, Lortholary O, Royer I, Lhote F, Darras-Joly C, Guillevin. Les manifestations digestives de la périartérite noueuse. Gastroentérol Clin Biol 1997; 21: 503-510.
54. Blétry O et al. Manifestations cardiaques de la périartérite noueuse. Arch Mal Coeur 1980; 73: 1027-1036.
55. Lhote F et al. Les manifestations pleurales au cours de la périartérite noueuse, de la maladie de Wegener et du lupus mateux systémique. Ann Méd Interne (Paris) 1992; 143: 228-232.
56. Guillevin et al. Systemic vasculitis of the polyarteritis nodosa group and infections with hepatitis B virus: a study in 98 patients. Eur J Intern Med 1990; 1: 97-105.
57. Guillevin et al. Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients. Ann Méd Interne (Paris) 1992; 143 (suppl 1): 63-74.
58. Piette JC et al. Systemic polyarteritis nodosa diagnosed at hysterectomy. Am J Med 1987; 82: 836-838.
59. Trépo C et al. The role of circulating hepatitis B antigen/antibody immune complexes in the pathogenesis of vascular and hepatic manifestations in polyarteritis nodosa. J Clin Pathol 1974; 27: 863-886.
60. Moreland LW, Ball GV. Cutaneous polyarteritis nodosa. Am J Med 1990; 88: 426-430.
61. Guillevin L, Ronco P, Verroust P Circulating immune complexes in systemic necrotizing vasculitis of the polyarteritis nodosa group. Comparison of HBV-related polyarteritis nodosa and Churg-Strauss angiitis J Autoimmun 1990; 3: 789-792
62. Guillevin L et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome: 62 patients. J Rheumatol 1993; 20: 1345-1349.
63. Pusey CD, Gaskin G. Disease association with anti-neutrophil cytoplasmic antibodies. In: Gross WL (ed). ANCA-associated vasculitis Plenum Press: New York and London, 1993, pp 145-155.
64. Hauschild S et al ANCA in systemic vasculitis, collagen vascular disorders and inflammatory bowel diseases. In: Gross WL (ed). ANCA-associated vasculitis Plenum Press: New York and London, 1993, pp 245-251.
65. Bron KM, Strott CA, Shapiro AP The diagnostic value of angiographic observations in polyarteritis nodosa. A case of multiple aneurysms in the visceral organs. Arch Intern Med 1965; 116: 450-454.
66. Hekali P et al. Diagnostic significance of angiographically observed visceral naeurysms with regard to polyarteritis nodosa. Acta Radiol 1991; 32: 143-148.
67. Giullevin L et al. Regressing aneurysms in polyarteritis nodosa related to hepatitis B virus. Eur J Intern Med 1990; 1: 267-272.
68. Guillevin et al. Antineutrophil cytoplasm antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis nodosa group. Br J Rheum 1996; 35: 958-964.
69. Cosserat J et al. Embolies multiples de cholestérol simulant une périartérite noueuse. Presse Méd 1992; 21: 557-564.
70. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. Q J Med 1948; 17: 175-202.
71. Dupré-Goudable C. et al Micropolyarténte. Nephrologie 1992; 3: 283-286.
72. Wainwright J, Davson J. The renal appearances in the microscopic form of periarteritis nodosa J Pathol Bacteriol 1948; 62: 189-196.
73. Haworth SJ et al. Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteritis. Br Med J 1985; 290: 1775-1778
74. Nada AK et al. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 1990; 65: 847-856.
75. Matsumoto T et al. The lung is polyarteritis nodosa: a pathologic study of 10 cases. Hum Pathol 1993, 24. 717-724.
76. Davenport, A, Lock RJ, Wallington TB, Feest TG Clinical significance of antineutrophil cytoplasm antibodies detected by standardized indirect immunofluorescence assay. Q J Med 1994; 87: 291-299.
77. Niles JL. Value of test for antineutrophil cytoplasmic autoantibodies in the diagnosis and treatment of vasculitis. Curr Opin Rheumatol 1993; 5: 18-24.
78. Lhote F, Cohen P, Généreau T, Gayraud M, Guillevim L. Microscopic polyangiitis. Clinical aspects and treatment. Ann Méd Interne (Paris) 1996; 147: 165-177.
79. Falk RJ et al. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990; 113: 656-663.
80. Csernok E et al. Membrane surface proteinase and intracytoplasmic immunoglobulin on neutrophils from patients with ANCA-associated vaculitides. In: Gross WL (ed). ANCA-associated vasculitis Plenum Press: New York and London, 1993, pp 45-50.
81. Cohen-Tervaert JW, Elema ID, Kallenberg CGM. Clinical histopathological association of 29kD-ANCA and MPO-ANCA. APMIS 1990; 98 (Suppl 19): 35.
82. Gaskin G, Clutterbuck EJ, Pusey CD. Renal disease in the Churg-Strauss syndrome. Contrib Nephrol 1991; 94: 58-65.
83. S3 Cohen P, Gayraud M, Lhote F, Jarrousse B, Guilievin L. Possible triggering factors for Churg-Strauss syndrome: a retrospective analysis of 97 patients. Arthritis Rheum 1997; 40 (Supplement): S166 (abstract 812).
84. Phanuphak P, Kohler PF. Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am J Med 1980; 68. 479-485.
85. Guillevin L. Amouroux J, Arbeille B, Boura R. Churg-Strauss angiitis. Arguments favoring the responsibility of inhaled antigens. Chest 1991; 100: 1472-1473.
86. Chumbley LC, Harrison EG, De Remee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Mayo Clin Proc 1977; 52: 477-484.
87. Guillevin L, Guittard T, Blétry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 1987; 165: 165-172.
88. Hass C et al. L'angéite allergique avec granulomatose. syndrome de Churg et Strauss. Etude reétrospective de 16 observations. Ann Méd Interne (Paris) 1991; 142: 335-342.
89. Abu-Shakra M et al. Outcome of polyarteritis nodosa and Churg-Strauss syndrome. An analysis of twenty-five patients. Arthritis Rheum 1994; 37: 1798-1803.
90. Lhote F, Guillevm L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am 1995; 21: 911-947.
91. Guillevin L et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 1996; 75: 17-28.
92. Allen JN, Davis WB. Eosinophilic lung diseases Am J Respir Crit Care Med 1994; 150: 1423-1438.
93. Bagenstoss AH, Shick RM, Polley HF. The effect of cortisone on the lesions of periarteritis nodosa [abstract]. Am J Pathol 1950; 26: 709.
94. Fauci AS, Doppman JL, Wolff SM. Cyclophosphamide-induced remission in advanced polyarteritis nodosa. Am J Med 1978; 64: 890-894.
95. Fauci AS et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. New Engl J Med 1979; 301: 235-238.
96. Guillevin L et al. Long-term follow-up after treatment of periarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchanges and cyclophosphamide to steroids and plasma exchanges. A prospective randomized trial of 71 patients. J Rkeumatol 1991; 18: 567-574.
97. Guillevin L et al. Lack of superiority of steroids and plasma exchanges to steroids in the treatment of polyarteritis nodosa and Churg-Strauss angiitis. A prospective randomized trial in 78 patients. Arthritis Rheum 1992; 35: 208-215.
98. Giullevm L et al. Treatment of polyarteritis nodosa related to hepatitis B virus with short-term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 1993; 20: 289-298.
99. Guillevin L et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53: 334-337.
100. Guillevin L et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus steroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-1645.
101. Gayraud M et al and the French Cooperative Study Group for Vasculitides. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol 1997; 36: 1290-1297
102. Ariel J De la corticothérapie classique à l'assaut cortisonique. Ann Méd Interne (Paris) 1994; 145 (suppl 2): 5-10.
103. Renoux M, Hilliquin P, Menkes CJ Les bolus de méthylprednisolone en rhumatologie. Ann Méd Interne (Paris) 1994; 145: 133-139.
104. Still well TJ et al. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31: 465-470.
105. Baker GL et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987; 83: 1-9.
106. Godeau B et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994; 21: 246-251.
107. Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone treatment in systemic rheumatoid vasculitis. Am J Med 1984; 76 377-384.
108. De Vita S, Neri R, Bombardiert S. Cyclophosphamide pulses in the treatment of rheumatic diseases: an update. Clin Exp Rheumatol 1991; 9: 179-193.
109. Généreau T et al. Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low dose cyclophosphamide after failure of pulse IV high dose regimen in 4 patients. Br J Rheumatol 1994; 33: 959-962.
110. Lhote F, Guillevin L. Indications of plasma exchanges in the treatment of polyarteritis nodosa, Churg-Strauss syndrome and other systemic vascuhtides. Transfus Sci 1996; 17: 211-213.
111. Gayraud M, Giullevin L. Cohen P, Jarrousse B. Analysis of long-term follow-up of 278 patients with perarteritis nodosa (PAN) or Churg-Strauss syndrome (CSS). Arthritis Rheum 1997; 40 (Supplement): S166 (abstract 811).
112. Savage COS, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997; 349: 553-558.
113. Jayne DR, Rasmussen N for the European Community Systemic Vasculitis Clinical Trial Study Group (ECSYSVASTRIAL). Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community systemic vasculitis clinical trials study group. Mayo Clin Proc 1997; 72: 737-747.
114. Pusey CD et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-763.
115. Newbuerger JW et al The treatment of Kawasaki syndrome with intravenous gamma globulin. New Engl J Med 1986; 315: 341-347.
116. Schifferh JA. Adverse effects of intravenous immunoglobulins. Transfus Sci 1992; 13: 331-338.
117. Jayne DRW. Intravenous immunoglobulins in the therapy of systemic vasculitis Transfus Sci 1992; 13: 317-324.
118. Richter C et al. Treatment of ANCA-associated systemic vasculitis with high-dose intravenous immunoglobulin. Arthritis Rheum 1994; 37 (suppl 9): S353 (abstract 1154).
119. Mathieson PW et al. Monoclonal-antibody therapy in systemic vasculitis. New Engl J Med 1990; 323: 250-254